Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2006

View Archived Issues

Novel anti-Trx-1 reductase prodrugs demonstrate antitumor activity

Preclinical profile of promising clinical candidate ACP-103

No serious side effects in ongoing phase II study of NX-1207

FDA review of Keflex sNDA ongoing

Spectrum closes acquisition of Targent oncology assets

Boston Scientific completes combination with Guidant

New phase IIIb extension trial for Acapodene

NDA submission planned for room-temperature formulation of MNTX

Astellas closes CNS research in Edinburgh

FAST I phase III trial of icatibant for HAE completes randomization

BioVant shows potential as adjuvant for avian flu vaccine

U.S. study of NOV-205 for hepatitis C cleared to begin

Stem cell therapy product PLX-1 investigated in new preclinical study

FDA extends review for Sparlon in ADHD

Alcon and Amgen collaborate on therapeutics for eye diseases

Neuropharma advances NP-031112 for Alzheimer's disease into clinic

Fesoterodine superior to tolterodine in overactive bladder trial

Urinary incontinence improved by cizolirtine in overactive bladder patients

Pfizer announces new tolterodine study and releases data on overactive bladder prevalence

CYT005-AllQbG10 shows long-term efficacy in house dust mite allergy patients

TG-4001 enables avoidance of surgery in CIN2/3 patients

Amitiza now available for chronic idiopathic constipation

Novel treatment options for autoimmune disorders described in recent patent literature

Recent patents report new treatments for gastrointestinal disorders

New androgen receptor antagonists emerge from Pfizer R&D

PharmaMar presents preclinical data on its new Kahalalide F derivative

Arius Research presents data on their new anticancer antibodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.